日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells.

PURE-seq 整合了 FACS 和 PIP-seq,用于超稀有细胞的单细胞基因组学研究。

Pan Sixuan, Fernández-Maestre Inés, Chang Kai-Chun, Van Haver Stéphane, Wereski Matthew G, Haugh Alexandra M, Tsai Katy K, Daud Adil I, Bowman Robert L, Vasudevan Harish N, Levine Ross L, Abate Adam R

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors

一项评估 TLR9 激动剂 cavrotolimod 与抗 PD-1 抗体联合治疗晚期实体瘤患者的安全性、有效性和免疫效应的 1b/2 期研究

Milhem, Mohammed M; Wise-Draper, Trisha M; Chandra, Sunandana; Hanna, Glenn J; Laux, Douglas E; Medina, Theresa M; Ansstas, George; Daud, Adil; Kelly, Ciara M; O'Day, Steven J; Perez, Cesar A; Wong, Michael K; Friedlander, Philip A; Kristedja, Timothy S; Burgess, Melissa A; Cowey, C Lance; Hanks, Brent A; Weight, Ryan M; Daniel, Weston L; Feltner, Douglas E; Mix, Scott; Sindelar, Laurel; Bexon, Alice S; Bexon, Martin F; Michel, Robert E; Bhatia, Shailender

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study

在程序性死亡受体1阻断耐药的黑色素瘤患者中,瘤内注射维杜托利莫德作为单药治疗或与帕博利珠单抗联合治疗:一项1b期研究的最终分析

Milhem, Mohammed M; Zakharia, Yousef; Davar, Diwakar; Buchbinder, Elizabeth I; Medina, Theresa; Daud, Adil; Ribas, Antoni; Chmielowski, Bartosz; Niu, Jiaxin; Gibney, Geoffrey T; Margolin, Kim; Olszanski, Anthony J; Mehmi, Inderjit; Sato, Takami; Shaheen, Montaser; Zhao, Luping; Kelley, Heather; Liu, Hong; Kumar, Sujatha; Bobilev, Dmitri; Krieg, Arthur M; Wooldridge, James E; Kirkwood, John M

Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events

区分帮助与伤害:辅助性T细胞亚群与免疫相关不良事件

Haugh, Alexandra M; Daud, Adil I

Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations

针对皮肤黑色素瘤的靶向DNA测序可识别预后和预测性改变

Haugh, Alexandra M; Osorio, Robert C; Francois, Rony A; Tawil, Michael E; Tsai, Katy K; Tetzlaff, Michael; Daud, Adil; Vasudevan, Harish N

Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors

转移性黑色素瘤至小肠:在免疫疗法和免疫检查点抑制剂时代,转移灶切除术仍然有效。

Wong, Paul; Wisneski, Andrew D; Tsai, Katy K; Chang, Tammy T; Hirose, Kenzo; Nakakura, Eric K; Daud, Adil I; Maker, Ajay V; Corvera, Carlos U

Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response

帕博利珠单抗、伊匹木单抗和阿司匹林治疗黑色素瘤的II期临床试验:临床结果和疗效转化预测因子

Quandt, Zoe; Jacob, Saya; Fadlullah, Muhammad Zaki Hidayatullah; Wu, Chaorong; Wu, Clinton; Huppert, Laura; Levine, Lauren S; Sison, Paula; Tsai, Katy K; Chow, Melissa; Kang, Jee Hye; Hwang, Jimmy; Lee, James C; Oglesby, Ariel; Venegas, Jessica; Brintz, Ben J; Tan, Aik Choon; Anderson, Mark S; Rosenblum, Michael D; Young, Arabella; Daud, Adil I

Pulsed Electric Fields in Oncology: A Snapshot of Current Clinical Practices and Research Directions from the 4th World Congress of Electroporation

脉冲电场在肿瘤学中的应用:第四届世界电穿孔大会对当前临床实践和研究方向的概述

Campana, Luca G; Daud, Adil; Lancellotti, Francesco; Arroyo, Julio P; Davalos, Rafael V; Di Prata, Claudia; Gehl, Julie

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

一项针对晚期实体瘤患者的泛RAF抑制剂托沃拉非尼的I期研究,随后在转移性黑色素瘤患者中开展剂量扩展研究。

Rasco, Drew W; Medina, Theresa; Corrie, Pippa; Pavlick, Anna C; Middleton, Mark R; Lorigan, Paul; Hebert, Chris; Plummer, Ruth; Larkin, James; Agarwala, Sanjiv S; Daud, Adil I; Qiu, Jiaheng; Bozon, Viviana; Kneissl, Michelle; Barry, Elly; Olszanski, Anthony J

Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy

组织特异性调节性T细胞在癌症转移中的作用:精准免疫治疗的契机

Huppert, Laura A; Green, Michael D; Kim, Luke; Chow, Christine; Leyfman, Yan; Daud, Adil I; Lee, James C